Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Reports collaboration and license revenue related to the Kyorin Agreement was $200K for the year ended 2024, which consisted of drug product ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study ...

Cardiac sarcoidosis (CS) was a complication in about 10% of pulmonary sarcoidosis (PS) cases, investigators reported in Respiratory Medicine. The retrospective study assessed the prevalence, incidence ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...

The following is a summary of "Respiratory abnormalities in sarcoidosis: physiopathology and early diagnosis using ...

“As we look to position efzofitimod as a potential chronic, maintenance therapy for patients with pulmonary sarcoidosis that can reduce or eliminate the use of oral corticosteroids, we are ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), on Friday announced that the independent Data and Safety Monitoring Board or DSMB has completed a fourth pre-planned interim safety analysis for the ongoing ...